I agree. The FED has boxed themselves in for June or July, no turning back now or their credibility is smoked. I will be looking for an entry point in infrastructure and defense stocks if we get a broad market selloff. Pharma and bios not so much, Both Trump& Clinton will looking for ways to cut drug prices next year.
I sold a lot of my positions today Took a small stake in UVXY as a hedge for the balance. Just can't get excited about the market at this level.
Way to many people in this now with pie in the sky ideas. Bottom line the trading event went as the longs had hoped. Take your profits and reload at lower levels. There is nothing the company can do now other then to show sales growth period. And technically the chart has to many gaps to fill below and we are now over bought on the short term, a 5% correction is due for the market over the summer months and there is no reason to think RLYP isn't going down with it.
until then to many gaps in the chart pattern, the market makers will see to it that all are filled first. I expect to see a 15 print sometime in the near future, absent any PR from management. The track record of small bios going from the lab to market is dismal and this one is no different.
They don't own much. As per latest proxy # of shares beneficially owned 54,063, number of shares exercisable within 60 days 1,656744 = 3.76% They can't stop a hostile bid.
CEO Heiden buy's 11,812 @ 18.20 0n 5/16/ So we have the co. with a buy back program and the insiders buying and adding to their individual holdings, all good signs . If they hit on their earnings& rev. growth numbers for year the stock should be materially higher from the current price.
Sentiment: Strong Buy
That's the same spot I got 500 at and lowered my bid to 13.11 but only got 200 at that number. This will take time to work but the odds are it will be a money maker in a couple of years. I still believe that it won't be independent for long. Big pharma is just to starved for growth either a buyout get's done friendly or they hostile.
Received the 2015 annual report and proxy for 2016 shareholder meeting yesterday. Pg.#5 worth noting, We estimate that there are approximately 3 million patients with CKD stage 3or 4 and/or HF with hyperkalemia in the United States Do the math on that number with just 10% penetration.
Sentiment: Strong Buy